Jul 12, 2018
CStone's PD-1 inhibitor CS1003 receives clinical trial approval in China
Jun 13, 2018
CStone Pharmaceuticals Initiates Two Pivotal Phase II Studies of the Anti-PD-L1 Monoclonal Antibody CS1001
Jun 04, 2018
Polaris Group Announces Results of a Phase 1 Clinical Study with its Lead Therapeutic Candidate ADI-PEG 20 in Combination with Pembrolizumab For Advanced Solid Tumors
Jun 04, 2018
Merck KGaA, Darmstadt, Germany Presents Updated Clinical Results for Bifunctional Immunotherapy M7824 at ASCO 2018
May 14, 2018
CStone announces first patient dosing with anti-PD-1 antibody CS1003 in Phase I study in Australia
May 14, 2018
Tocagen to Present Preclinical Data on Anti-PD-L1 Product Candidate Toca 521 at the 2018 Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT)
Apr 06, 2018
Global Immuno-Oncology Market 2018-2022 - Market is Anticipated to Cross US$ 100 Billion
Mar 22, 2018
Deerfield Commits $36 Million to Advance Dracen's Novel Immuno-Metabolism Pipeline
Mar 14, 2018
Halozyme To Present Data From Six Nonclinical Studies At American Association Of Cancer Research Annual Conference
Feb 01, 2018
Syndax Announces Immuno-Oncology Clinical Trial Collaboration with AstraZeneca
Jan 17, 2018
Celsee and IncellDx Sign Co-Commercialization Agreement Following Successful Lung Cancer/CTC PD-L1 Feasibility Study
Jan 11, 2018
Forty Seven Inc. to Collaborate on a Novel Immuno-Oncology Combination for Leukemia and Bladder Cancer
Dec 27, 2017
CStone files CS1003, an anti-PD-1 antibody, for clinical trial approval in Australia
Dec 19, 2017
GigaGen to Develop Human Antibodies Against 17 Immuno-oncology Targets
Dec 09, 2017
ARMO BioSciences Presents Data from its Phase 1b Trial in Non-Small Cell Lung Cancer at ESMO Immuno Oncology Congress 2017
Nov 28, 2017
Biocept and UC San Diego Medical Center Announce Clinical Study Collaboration to Demonstrate Utility of Biocept's Liquid Biopsy Test in Immunotherapy
Nov 10, 2017
Definiens Presents Cutting-Edge Data at the 32nd Annual SITC Congress
Nov 07, 2017
New Data Featuring Nektar Therapeutics' Wholly-Owned Immuno-Oncology Pipeline to be Presented at the 2017 Society for Immunotherapy of Cancer 32nd Annual Meeting
Oct 20, 2017
CStone Pharmaceuticals Announces Dosing the First Patient of CS1001: China's First Fully Human, Full-length Anti-PD-L1 Monoclonal Antibody
Oct 19, 2017
GIMDx, Inc. and IncellDx, Inc. Announce OEM and International Distribution Agreement for Single Cell Immuno-Oncology and Oncology Diagnostic Products in China